心脏代谢药物标中的蛋白质 - 连接体相互作用:专注于减肥和心脏保护
Errikos Petsas1, Despoina P Kiouri1, Nikitas Georgiou1,2
1Laboratory of Organic Chemistry, Department of Chemistry, National and Kapodistrian University of Athens, 11571 Athens, Greece.
Molecules (Basel, Switzerland)
|November 13, 2025
概括
新的多向药物显示出治疗心脏代谢疾病的前景,通过同时解决血糖,体重,胆固醇和炎症. 这些综合疗法旨在改善心血管和代谢健康,并减少组合药物风险.
科学领域:
- 药理学 药理学是指药理学的学科.
- 分子生物学分子生物学
- 心脏病学 心脏病学
背景情况:
- 心脏代谢性疾病 (CVD) 是一个主要的全球健康负担,由心血管和代谢失调驱动.
- 目前的治疗方法通常涉及多种药物,增加复杂性和风险.
研究的目的:
- 审查心脏代谢调节中的六个关键治疗点.
- 分析结构特征,控制连接剂的有效性和特异性.
- 为指导下一代多标配体的设计,用于综合疗法.
主要方法:
- 对六个目标的精选结构数据集的分析:GLP-1R,GIPR,FGFR1/β-Klotho,PCSK9,NF-κB和NLRP3炎症体.
- 关键的绑定域特征的映射.
- 对双重激动剂和抑制剂的现有文献的审查.
主要成果:
- 双重GLP-1R/GIPR激动剂 (例如,蒂尔泽帕提德) 改善血糖控制和体重.
- 抑制PCSK9,NF-κB和NLRP3的抑制剂降低胆固醇和炎症,提供心脏保护.
- 在确定为合理药物设计的目标中,互补的绑定动机.
结论:
- 下一代多标配体可以提供结合的心血管和代谢益处.
- 综合剂可以降低与复杂药物组合相关的风险.
- 同时针对多个途径代表了对心血管疾病的有希望的治疗策略.
相关概念视频
Ligand Binding Sites
14.9K
Proteins are dynamic macromolecules that carry out a wide variety of essential processes; however, the activities of most proteins depend on their interactions with other molecules or ions, known as ligands.
Protein-ligand interactions are quite specific; even though numerous potential ligands surround a cellular protein at any given time, only a particular ligand can bind to that protein. Moreover, a ligand binds only to a dedicated area on the surface of the protein, known as the...
Protein-ligand interactions are quite specific; even though numerous potential ligands surround a cellular protein at any given time, only a particular ligand can bind to that protein. Moreover, a ligand binds only to a dedicated area on the surface of the protein, known as the...
14.9K
Ligand Binding Sites
8.5K
8.5K
Transducer Mechanism: Enzyme-Linked Receptors
3.8K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
3.8K
Ligand Binding and Linkage
3.9K
3.9K
Ligand Binding and Linkage
5.4K
Allosteric proteins have more than one ligand binding site; the binding of a ligand to any of these sites influences the binding of ligands to the other sites. When a protein is allosteric, its binding sites are called coupled or linked. In the case of enzymes, the site that binds to the substrate is known as the active site and the other site is known as the regulatory site. When a ligand binds to the regulatory site, this leads to conformational changes in the protein that can influence...
5.4K
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
230
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
230


